Rezultati - Dong‐Wan Kim
- Showing 1 - 20 results of 128
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
The architecture of SARS-CoV-2 transcriptome od Dong-Wan Kim, Joo-Yeon Lee, Jeong‐Sun Yang, Jun Won Kim, V. Narry Kim, Hyeshik Chang
Izdano 2020Pré-impressão -
8
The Architecture of SARS-CoV-2 Transcriptome od Dong-Wan Kim, Joo-Yeon Lee, Jeong-Sun Yang, Jun Won Kim, V. Narry Kim, Hyeshik Chang
Izdano 2020Artigo -
9
-
10
-
11
-
12
-
13
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor od Sehhoon Park, Seunggyun Ha, Se‐Hoon Lee, Jin Chul Paeng, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo
Izdano 2018Artigo -
14
-
15
Antibiotic use during the last days of life in cancer patients od Dong Yoon Oh, J. Kim, Dong‐Wan Kim, Seock‐Ah Im, T.Y. KIM, D. S. Heo, Y-J. Bang, N.K. KIM
Izdano 2006Artigo -
16
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis od Ryul Kim, Seokyung Hahn, Junghoon Shin, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo
Izdano 2015Revisão -
17
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma od Seong-Ho Kang, Bhumsuk Keam, Yong‐Oon Ahn, Ha-Ram Park, Miso Kim, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo
Izdano 2018Artigo -
18
-
19
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced... od Fiona Blackhall, Dong‐Wan Kim, Benjamin Besse, Hiroshi Nokihara, Ji‐Youn Han, Keith D. Wilner, Arlene Reisman, Shrividya Iyer, Vera Hirsh, Alice T. Shaw
Izdano 2014Artigo -
20
Iskalna orodja:
Sorodne teme
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Biology
Cancer research
Chemotherapy
Malignant pleural effusion
Epidermal growth factor receptor
Crizotinib
Gastroenterology
Confidence interval
Clinical endpoint
Clinical trial
Adverse effect
Gefitinib
Immunotherapy
Anaplastic lymphoma kinase
Gene
Pathology
Hazard ratio
ALK inhibitor
Genetics
Surgery
Biochemistry
Phases of clinical research
Receptor
Adenocarcinoma
Erlotinib